We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
WHO prequalifies a second malaria vaccine, a significant milestone in prevention of the disease.
- Abstract
The World Health Organization (WHO) has prequalified a second malaria vaccine, the R21/Matrix-M, for use in preventing malaria in children. This prequalification allows for larger access to the vaccine and enables procurement by UNICEF and funding support for deployment by Gavi, the Vaccine Alliance. The R21 vaccine, developed by Oxford University and manufactured by Serum Institute of India, is the second malaria vaccine to receive prequalification from WHO, following the RTS, S/AS01 vaccine. Malaria is a significant public health risk, particularly for children in the African Region, where nearly half a million children die from the disease each year. The prequalification of the R21/Matrix-M vaccine is expected to increase the supply of malaria vaccines and benefit all children living in malaria-endemic areas.
- Subjects
MALARIA vaccines; PREVENTIVE medicine; MALARIA prevention; PUBLIC health surveillance; MOSQUITO-borne diseases; SMOKING cessation
- Publication
Neurosciences, 2024, Vol 29, Issue 2, p149
- ISSN
1319-6138
- Publication type
Article